Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 3/20 | 0.32 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.32 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24172621 | 0.89 | C3AR1 (0.36) | — | |
| SCHEMBL26466762 | 0.86 | ANPEP (0.30) | ANPEPRNPEPDNPEP | |
| SCHEMBL19487357 | 0.81 | KISS1R (0.31) | ANPEPRNPEPDNPEP | |
| SCHEMBL22536882 | 0.80 | GABRR1 (0.41) | — | |
| SCHEMBL15478602 | 0.77 | DPP4 (0.39) | — | |
| SCHEMBL20130643 | 0.77 | DPP4 (0.39) | — | |
| SCHEMBL15478607 | 0.76 | NPY4R (0.36) | — | |
| SCHEMBL14632143 | 0.76 | NPY4R (0.36) | — | |
| SCHEMBL24420295 | 0.76 | C3AR1 (0.35) | — | |
| SCHEMBL13769032 | 0.76 | NPY4R (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626144-B2 | Peptide derivatives and uses thereof | NOSOPHARM (FR) | 2020-04-21 | — | — | US | disclosed |
| US-20170298097-A1 | Peptide Derivatives and Uses Thereof | NOSOPHARM (FR) | 2017-10-19 | — | — | US | disclosed |
| US-20150328207-A1 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | AUSPEX PHARMACEUTICALS, INC. | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626144-B2 | Peptide derivatives and uses thereof | VIP, IAPP, NGLY1 | ANPEP 12/4885RNPEP 58/4885DNPEP 13/4885 |
| US-20150328207-A1 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | SLC18A2, SLC6A2, SLC18A1 | ANPEP 2380/4885RNPEP 2201/4885DNPEP 1957/4885 |
| US-20170298097-A1 | Peptide Derivatives and Uses Thereof | VIP, IAPP, NGLY1 | ANPEP 12/4885RNPEP 58/4885DNPEP 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.